AbCellera
UBC Faculty of Science
AbCellera is a UBC spin-off company pioneering the discovery and development of next-generation antibody medicines. What began as a bold scientific pursuit has grown into a global biotech company transforming how therapeutics are found and developed. Their powerful engine integrates cutting-edge technology, data science, and multidisciplinary expertise to search natural immune systems and identify antibodies that prevent and treat disease. By combining deep scientific insight with scalable innovation, AbCellera is advancing a pipeline of first-in-class and best-in-class therapies targeting cancer, autoimmune, metabolic, and endocrine disorders, improving health outcomes and saving lives.
Founders
Dr. Carl Hansen - CEO & Co-Founder
Dr. Véronique Lecault - Chief Technology Officer & Co-Founder
Dr. Kevin Heyries - Co-Founder
Daniel Da Costa - Co-Founder
Dr. Oleh Petriv - Co-Founder
Timeline
2025 Received $4.5M grant
2023 $300M co-investment from provincial and federal governments for campus expansion in
Vancouver, including a preclinical antibody development facility (Learn more)
2020 Raised $105M USD Series B financing to further advance world-leading antibody drug
discovery platform (Learn more)
Received $175.6M government grant to discover solutions for COVID-19 and build a
manufacturing facility for antibody drugs (Learn more)
Announced $483M USD IPO (Learn more)
2018 Raised $10M USD Series B financing to accelerate their therapeutic antibody
discovery business (Learn more)
2016 Received $645K grant to develop a test for tuberculosis
2014 UBC license completed
